AKT1 and breast carcinoma: Beyond PI3Ks, PIP5Ks and PIP4Ks are emerging as an attractive target for therapeutics in inflammation and breast cancer, as they generate PI(4,5)P2 at the plasma membrane, critical for activating the PI3K/AKT signaling pathway.